Clinical

Dataset Information

0

Safety of Cetuximab and Trifluridin Tipiracil as the Third-line Therapy in the RASwt mCRC


ABSTRACT: This was a single-arm, prospective study to investigate the safety of cetuximab in combination with trifluridin tipiracil (TAS-102) in the third-line treatment of Chinese patients with RAS wild-type mCRC.

DISEASE(S): Colorectal Neoplasms Malignant,Colorectal Neoplasms,Neoplasms

PROVIDER: 2398166 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 60837 | ecrin-mdr-crc
| 2202964 | ecrin-mdr-crc
| 2287666 | ecrin-mdr-crc
| 69888 | ecrin-mdr-crc
2023-03-31 | GSE226221 | GEO
| 2308817 | ecrin-mdr-crc
2024-08-26 | GSE275628 | GEO
| 2709221 | ecrin-mdr-crc
| 2717618 | ecrin-mdr-crc
| 14404 | ecrin-mdr-crc